This systematic review with meta-analysis sought to determine the protective effects of corticosteroids on clinical outcomes following coronary artery bypass grafting (CABG). Medline, Embase, Elsevier and Sciences online database as well as Google scholar literature were used for selecting appropriate studies with randomized controlled design. The effect sizes measured were odds ratio (OR) for categorical variables and weighted mean difference with 95% confidence interval (CI) for calculating differences between mean values of duration of hospitalization in intervention and control groups. Values of P < 0.1 for Q-test or I 2 > 50% indicated significant heterogeneity between the studies. The literature search of all major databases retrieved 3735 studies. After screening, a total of 45 trials were identified that reported outcomes. Pooled analysis was performed on incidence of atrial fibrillation (OR of 0.71; 95% CI: 0.59-0.86; P = 0.000), stroke (OR of 1.61; 95% CI: 0.63-4.1; P = 0.3), infection (OR of 1.03; 95% CI: 0.68-1.5; P = 0.8), re-infarction (OR of 0.88; 95% CI: 0.47-1.63; P = 0.6), length of ventilation time [weighted mean difference (WMD) of 0.257; 95% CI: 0.10-0.41; P = 0.00], length of hospital stay (WMD of −0.48; 95% CI: −0.66 to −0.3; P = 0.000), amount of blood loss (WMD of −124.05; 95% CI: −147.72 to −100.38; P = 0.00), re-exploration (OR of 1.25; 95% CI: 0.66-2.35; P = 0.4) and mortality (OR of 0.87; 95% CI: 0.46-1.64; P = 0.6). Overall, steroid prophylaxis in patients undergoing CABG could significantly reduce complications such as atrial fibrillation and length of hospital stay, but slightly increased the length of ventilation time. On the other hand, no significant impact on the incidence of infection was observed compared with the placebo.
INTRODUCTION
Coronary artery bypass grafting (CABG) and cardiopulmonary bypass (CPB) induce a systemic inflammatory response characterized by leucocytes and complement activation, and elevated levels of inflammatory mediators that may contribute to postoperative complications including atrial fibrillation (AF), infections, organ dysfunction, blood loss, prolonged duration of intensive care unit (ICU) and hospital stay, as well as increase in costs of therapy [1, 2] . AF is the most frequent complication after cardiac surgery. Incidence of AF has been reported in 20-50% of patients following CABG and is even higher after combined CABG and valve surgery. Factors predictive of postoperative AF (POAF) include advanced age, male sex, body mass index >30, atrial dilatation, prolonged aortic cross-clamp times, preoperative leucocytosis and
METHODS AND MATERIALS

Literature search
A comprehensive literature search was conducted in major electronic databases (Medline/Pubmed, Embase, Elsevier, Sciences online database and Google scholar) from their inception through 30 July 2014 to identify the RCTs reporting the effects of corticosteroids on the complications following cardiac surgery. Predefined search terms included 'glucocorticoid', 'steroid', 'hydrocortisone', 'dexamethasone', 'methylprednisolone' and 'cardiac surgery', 'cardiothoracic surgery', 'heart surgery', 'cardiopulmonary bypass', 'CPB', 'coronary artery bypass grafting', 'CABG', 'CAB'. No language restrictions were applied. All retrieved references of the included RCTs were also reviewed to determine additional studies not indexed in the common databases. Studies were included into the analysis when they met the following criteria: (i) RCTs about comparison of steroids with a control group, (ii) adult patients undergoing CABG surgery (off-pump or on-pump) alone or combined with valvular surgery and [3] reporting data on the incidence of postoperative complications according to our review-checklist. In addition, abstracts without peer-review publications of manuscripts were not included.
Data extraction and outcome measures
Two investigators (Sadegh Ali-Hassan-Sayegh and Fatemeh Haddad) extracted the data independently, and discrepancies were resolved via a consensus standardized abstraction checklist used for recording data in each study. Data retrieved from the trials included author's name, type of surgery (CABG alone or CABG combined with valvular surgery), type of CABG surgery (on-pump or off-pump), study design, type of controls (placebo or not), type of blinding (double-blinded or not), details of therapeutic regimens, sample size, mean age and gender. The incidence of postoperative AF, stroke, renal disease, infection, myocardial infarction, length of ventilation time, ICU and hospital stay, amount of bleeding, re-exploration for bleeding and mortality were recorded for each group. The primary effect measure was the incidence rate of POAF during hospital stay or over follow-up. For exploration of heterogeneity among trials, a subgroup analysis of disparities in the patients' characteristics was performed for (i) average age (<65 years vs ≥65 years), (ii) percentage of males (<80% vs ≥80%), (iii) hypertension (≤70% vs >70%), (iv) diabetes (≤30% vs >30%), (v) dose of steroids (low, medium and high), (vi) type of surgery (CABG alone vs CABG combined valvular surgery) and (vii) type of CABG (on-pump vs off-pump).
Definitions
The following end-points were defined: new onset AF was considered when it occurred before hospital discharge. Postoperative mortality was considered as all-cause mortality occurring up to 30 days postoperatively or before hospital discharge. The length of mechanical ventilation support was measured in hours, and hospital stay was measured in days. Postoperative infections include any type of infection occurring after surgery. Postoperative chest tube drainage was measured in millilitres (ml). We defined total CS use <1000 mg hydrocortisone or equivalent as low dose, the total CS use >10 000 mg hydrocortisone or equivalent as high dose and the total CS use between 1000 and 10 000 mg hydrocortisone or equivalent as medium dose.
Statistical analysis, publication bias and quality assessment
Data were analysed by STATA version 11.0 utilizing METAN and METABIAS modules. The effect sizes measured were odds ratio (OR) with 95% confidence interval (CI) for categorical variables. For non-categorical data, the standard mean difference with 95% CI was used for calculating differences between intervention and control groups. OR <1 favoured CS and OR >1 favoured control. RCTs with no events in the two arms were discarded from pooled analysis. Forest plots were created for each outcome. A value of P < 0.1 for Q-test or I 2 > 50% indicated significant heterogeneity among the studies. Sample weighting assigned studies with larger sample sizes and more weight, and reduced the effect of sampling error because sampling error generally decreases as the sample size increases. Heterogeneity among trials was addressed by applying a random effect model when indicated. The presence of publication bias was evaluated using the Begg and Egger tests. Quality assessment of RCTs was performed using the Jadad score. The Jadad score assesses three items including randomization (0-2 points), blinding of study (0-2 points) and withdrawals and drop-outs (0-1 points). Higher scores indicate better reporting ('high' quality: 5; 'good' quality: 3-4; 'poor' quality: 0-2). Results were considered statistically significant at P-values <0.05.
RESULTS
Literature search strategy and included trials
Literature search retrieved 3735 studies from screened databases of which 3231 (86.5%) were excluded after initial review. Of 504 primary included studies, 459 were excluded after detailed evaluation due to insufficient reporting of end-points of interest. The final analysis included 45 RCTs. Details of demographic characteristics have been presented in Table 1 .
STUDY CHARACTERISTICS, EFFECT MEASURES AND CLINICAL OUTCOMES
Postoperative atrial fibrillation
A total of 2451 patients were included from 24 RCTs, which reported data on POAF. Patient population of RCTs ranged from 20 to 305. Of 2451 patients, 1271 cases were allocated to CS, and 1180 cases to the control group ( Table 2 ). The overall incidence of POAF was 24.7% ranging from 6.4 to 43.9%. POAF occurred in 21.5% in the CS group, and 28.09% in the control group. Pooled treatment effect analysis revealed that CS therapy significantly reduced the incidence of POAF with an OR of 0.71 (95% CI: 0.59-0.86; P = 0.000) using a random model (Fig. 1 ). Significant heterogeneity was observed among the RCTs (χ 2 = 35.57, I 2 = 35.3, P = 0.04). Subgroup analysis showed that CS had anti-arrhythmic effects in ages above and below 65 years, male and female, diabetic and non-diabetic patients (Supplementary material, Table S1 ). A subgroup analysis of the steroid dosage revealed that medium dose of CS significantly reduced the incidence of POAF with an OR of 0.59 (CI: 0.43-0.78; P = 0.000), whereas low and high doses of CS Continued could not reduce incidence of POAF (Supplementary material, Table S1 ). Begg and Egger tests showed that there was no potential publication bias among the included RCTs (Begg test, P = 0.346; Egger test, P = 0.346).
Postoperative stroke
A total of 1423 patients were included from 8 RCTs, which reported data on postoperative stroke (Table 2) . After removing RCTs with no events in two arms, a total of 1256 patients from 5 studies were enrolled in the present meta-analysis. Patient population of RCTs ranged from 60 to 737. From 1256 patients, 622 cases were allocated to CS and 634 to the control group. The overall incidence of stroke was 1.4% ranging from 0.8 to 4.3%. Stroke occurred in 1.7% of the cases in the CS group and 1.1% in the control group. Pooled treatment effect analysis revealed that CS therapy could not reduce incidence of stroke after surgery with an OR of 1.61 (95% CI: 0.63-4.1; P = 0.3) using a fixed model (Supplementary material, Fig. S1 ). No significant heterogeneity was observed among the RCTs (χ 2 = 2.91, I 2 = 0.0%, P = 0.5). A subgroup analysis showed that CS did not have anti-stroke effects in ages above and below 65 years, male and female, diabetic and non-diabetic patients (Supplementary material, Table S1 ). All doses of CS (low, medium and high) did not have preventing effects on stroke after surgery (Supplementary material, Table S1 ). Begg and Egger tests showed no potential publication bias among the included RCTs (Begg test, P = 0.805; Egger test, P = 0.805).
Postoperative infection
A total of 2060 patients were included from 23 RCTs, which reported data on postoperative infection (Table 2) . After removing RCTs with no events in two arms, a total of 1749 patients from 15 studies were enrolled in the meta-analysis. Patient population of RCTs ranged from 34 to 294 patients. From 1749 patients, 874 cases were allocated to the CS group and 875 to the control group. The overall incidence of infection was 5.43% ranging from 0.9 to 14.1%. Infections occurred in 5.4% of the cases in the CS group and 5.3% in the control group. Pooled treatment effect analysis revealed that CS therapy did not increase incidence of postoperative infection with an OR of 1.03 (95% CI: 0.68-1.5; P = 0.8) using a fixed model (Fig. 2) . No significant heterogeneity was observed among the RCTs (χ 2 = 6.71, I 2 = 0.0%, P = 0.9). A subgroup analysis showed that CS did not increase incidence of infection in ages above and below 65 years, male and female, diabetic and non-diabetic patients (Supplementary material, Table S1 ). All doses of CS (low, medium and high) did not have increasing effects on infection after surgery (Supplementary material, Table S1 ). Begg and Egger tests showed no potential publication bias among the included RCTs (Begg test, P = 0.369; Egger test, P = 0.369).
Postoperative myocardial infarction
A total of 1258 patients were included from 12 RCTs, which reported data on postoperative myocardial infarction (MI) ( Table 2 ). After removing one single RCT with two zero-columns, a total of 1234 patients from 11 studies were enrolled in our analysis. Patient population of RCTs ranged from 20 to 294. From 1234 patients, 628 cases were allocated to CS and 606 to the control group. The overall incidence of MI was 3.07% ranging from 0.68 to 6.6%. MI occurred in 2.8% of the cases in the CS group and 3.3% in the control group. 
STATE OF THE ART
Continued
Pooled treatment effect analysis revealed that CS therapy did not have ability for reducing the incidence of MI after surgery with an OR of 0.88 (95% CI: 0.47-1.63; P = 0.6) using a fixed model (Supplementary material, Fig. S2 ). No significant heterogeneity was observed among the RCTs (χ 2 = 7.02, I 2 = 0.0%, P = 0.7). All doses of CS (low, medium and high) could not decrease MI after surgery (Supplementary material, Table S1 ). Begg and Egger tests showed that there was no potential publication bias among the included RCTs (Begg test, P = 0.6; Egger test, P = 0.681).
Postoperative duration of ventilation
A total of 2653 patients were included from 29 RCTs, which reported data on postoperative duration of ventilation time (Table 2) . Mean duration for all trials was 11.55 ± 5.93 h with 11.63 ± 6.36 for CS and 11.47 ± 5.51 for the control group. Applying a random effect model, pooled analysis revealed that CS therapy succeeded significantly in reducing duration of ventilation with a WMD of 0.257 (95% CI: 0.10-0.41; P = 0.00) (Supplementary material, Fig. S3 ). There was significant heterogeneity among the studies (χ 2 = 257.6, I 2 = 98.1%, P = 0.000). A subgroup analysis is presented in Supplementary material, Table S1 .
Postoperative length of hospital stay
Mean length of hospital stay (LHS) for 35 trials (1536 patients) was 9.7 ± 4 days with 9.4 ± 4.13 for the CS group and 10 ± 3.99 for the control group. Pooled analysis revealed that CS therapy could significantly reduce LHS with a WMD of −0.48 (95% CI: −0.66 to −0.3; P = 0.000) using a random effect model (Fig. 3) . Significant heterogeneity was observed among the RCTs (χ 2 = 288.9, I 2 = 91.7%, P = 0.000).
Postoperative blood loss
Mean amount of bleeding for all trials was 707.66 ± 325.87 ml with 681.44 ± 329.23 ml for CS and 733.88 ± 322.51 ml for the control group. Applying a random effect model, pooled analysis revealed that CS therapy succeeded strongly in reducing blood loss with a WMD of −124.05 (95% CI: −147.72 to −100.38; P = 0.00) (Fig. 4) . There was significant heterogeneity among the studies (χ 2 = 73.5, I 2 = 87.8%, P = 0.00). A subgroup analysis is presented in Supplementary material, Table S1 .
Postoperative re-exploration
Eleven RCTs reported data on postoperative re-exploration (Table 2) . Overall incidence of re-exploration was 2.28%, 2.55% in the CS group and 2.02% in the control group. In fact, 3 of 11 comparisons did not present any postoperative re-exploration events in two comparative arms; therefore, the remaining 8 RCTs (1584 patients) were used to perform the meta-analysis. Pooled treatment effect analysis revealed that CS therapy could not reduce incidence of postoperative re-exploration with an OR of 1.25 (95% CI: 0.66-2.35; P = 0.4) using a fixed model (Supplementary 
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material, Fig. S4 ). No significant heterogeneity was observed among the RCTs (χ 2 = 6.37, I 2 = 0.0%, P = 0.7).
Postoperative mortality
Twenty-three RCTs reported data on postoperative death (Table 2 ). Mortality occurred in 1.11% of the cases in the CS group and 1.29% in the control group. In fact, 9 of 23 comparisons did not present any postoperative death event in two comparative arms; therefore, the remaining 14 RCTs (2267 patients) were used to perform the meta-analysis. Pooled treatment effect analysis revealed that CS therapy could not reduce incidence of postoperative mortality with an OR of 0.87 (95% CI: 0.46-1.64; P = 0.6) using a fixed model (Supplementary material, Fig. S5 ). No significant heterogeneity was observed among the RCTs (χ 2 = 6.37, I 2 = 0.0%, P = 0.9). A subgroup analysis showed that CS did not decrease the incidence of mortality in ages above and below 65 years, male and female, diabetic and non-diabetic patients (Supplementary material, Table S1 ). All doses of CS (low, medium and high) did not have decreasing effects on death (Supplementary material, Table S1 ).
DISCUSSION
Nowadays, increasing incidence of coronary artery disease highlights the importance of CABG [1] . Despite its notable complications, CABG surgery is considered an elective treatment for patients with several significant stenoses of coronary arteries [2] . POAF is one of the main complications associated with increased morbidity and mortality [6] . AF occurs in 30% of patients following CABG, and rises up to 40-50% in combined CABG and valve surgery [6] . POAF can increase the incidence of stroke, thromboembolic events, and haemodynamic instability and, as a result, LHS [6] . Inflammatory responses after cardiac surgery are known to contribute to the pathogenesis of POAF [6] . Therefore, an increase in acute phase proteins, such as C-reactive protein and tumour necrosis factor, may be a predictor of new onset POAF [7] . Glucocorticoids as anti-inflammatory drugs are widely used in the treatment of inflammatory diseases [7, 8] . As the activated inflammatory processes in cardiac procedure can predispose the incidence of other complications, administration of corticosteroids for prophylaxis and their effects on clinical outcomes have always been taken into account [9] .
Our meta-analysis revealed that in general steroids were able to dramatically reduce the incidence of POAF. Interestingly, CSs in low and high doses were unable to reduce AF, whereas administration of a medium dose of CSs was associated with a great anti-arrhythmic effect. A possible explanation for this might be that fewer studies on low and high doses of CS have been performed and, as a result, in this study CSs in low and high doses did not have prophylactic effects on AF. Also, it can be related to the AF response to CS therapy, which is in normal distribution (bell curve) where the optimum effective dose is the medium. According to pharmacology, anti-inflammatory effects of CS are dose-dependent [10] . This fact was confirmed in our meta-analysis in a way that optimum dose was the medium one, and higher doses did not have more significant effects. Moreover, Liu et al. pointed out that CS prophylaxis in high dose had more anti-arrhythmic effects than in low dose. This finding suggests that high doses of corticosteroids may alter the phospholipid cell membrane, causing potassium flux across the cell membrane [10] .
Stroke is an important neurological complication after cardiac surgery occurring in 3% of cases [11, 58] . Predisposing factors for stroke are as follows: age >50 years, urgent or emergency surgery, aortic valve disease, history of AF prior to surgery, previous stroke and CPB time of more than 110 min [11, 58] . As CSs have antiarrhythmic effects, and can prevent the incidence of POAF, we investigated whether there is an effect of CS on stroke as well. The findings of our study revealed that CS was unable to reduce postoperative stroke statistically.
One of the possible downsides of applying CS perioperatively is that steroid-induced suppression could significantly increase the risk of infection [5] . For that reason, physicians avoid administering CS prior to high-risk surgical interventions [5, 10] . Also, one of the reasons why administration of CS is contraindicated in diabetic patients is that this category of patients are more susceptible to postoperative infections compared with non-diabetic patients and CS might worsen their condition [5] . The findings of our study indicated that administration of steroids did not increase the risk of infection at all. No study had investigated the effect of high dose of CS on infection; however, low and medium doses did not increase the incidence of infection. Furthermore, according to our subgroup analysis, the incidence of infection after administration of CS did not differ significantly in diabetic and non-diabetic patients. The findings of our study showed that CS resulted in a statistical increase in length of ventilation compared with the placebo group, implying that administration of steroids could lead to pulmonary functional disorders. Chaney et al. [12, 13] claimed that steroids could possibly increase the need for respiratory support through increasing pulmonary shunt and alveolar-arterial oxygen gradient. This rationalization is consistent with our findings. A subgroup analysis showed that length of ventilation following low and medium doses of CS was not significantly different compared with placebo group. However, if high doses of steroids were administered, mechanical ventilation time would intensely increase. Therefore, it can be summarized that when using high doses of steroids, pulmonary function of the patient should be thoroughly assessed, and taken into account. There is a relationship between inflammation and coagulation: that is, in inflammation process, coagulation system might get involved through three mechanisms: (i) activation of coagulation, (ii) down-regulation of natural anticoagulation, (iii) suppression of fibrinolysis. Since the activation of inflammatory and coagulation systems presents similar pathways, a better presentation of coagulation system with reduced thrombin generation may be the cause of reduced blood loss in therapy-based anti-inflammation [14] .
The findings of our study demonstrated that CS receivers had statistically less bleeding compared with the control group; however, the clinical significance for this effect is questionable. Nevertheless, there might be a slight relationship between inflammation and coagulation systems. Interestingly, our subgroup analysis showed that medium dose had a more prophylactic effect on haemorrhage than low dose. The current meta-analysis also stated that steroid prophylaxis had no effect on the incidence of MI, re-exploration and mortality in patients undergoing CABG. Factors leading to increase in LHS and postoperative clinical costs are as follows: incidence of POAF, major haemorrhage, nosocomial infections and increase in length of need for mechanical ventilation. The current study claimed that CS was able to remarkably decrease LHS, which indeed depends on reduction of surgical complications and improvement in clinical outcomes after CABG. In agreement with our study, Cappabianca et al. [5] also reported that steroids could reduce morbidity, surgical complications and LHS. As the number of patients analysed for several end-points, such as stroke and bleeding, was low, though statistically correct, the clinical conclusion regarding these end-points may be limited. Concluding steroid prophylaxis in patients undergoing CABG could significantly reduce complications such as AF, and LHS and increase length of ventilation time statistically. On the other hand, it did not increase the incidence of infection compared with the placebo. Steroids are able to improve clinical outcomes, and thus can be used as an effective safe treatment in CABG.
